THE BASIC PRINCIPLES OF THROMBOXANE B2

Contraindicated (one)bortezomib will improve the stage or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or moderate CYP2C19 inhibitors might boost mavacamten systemic exposure, leading to coronary heart failure due to systolic dysfunction.Unlock 38% additional drug discovery time and eradicate final